These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 21492364)

  • 41. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
    Kadowaki T; Kondo K
    Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study.
    Yki-Järvinen H; Rosenstock J; Durán-Garcia S; Pinnetti S; Bhattacharya S; Thiemann S; Patel S; Woerle HJ
    Diabetes Care; 2013 Dec; 36(12):3875-81. PubMed ID: 24062327
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
    Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
    Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.
    Yoon KH; Steinberg H; Teng R; Golm GT; Lee M; O'Neill EA; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2012 Aug; 14(8):745-52. PubMed ID: 22405352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study).
    Krishnappa M; Patil K; Parmar K; Trivedi P; Mody N; Shah C; Faldu K; Maroo S; ; Parmar D
    Cardiovasc Diabetol; 2020 Jun; 19(1):93. PubMed ID: 32560724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial.
    Kaku K
    Curr Med Res Opin; 2009 May; 25(5):1111-9. PubMed ID: 19309251
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
    Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
    Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
    Bell DS; Dharmalingam M; Kumar S; Sawakhande RB
    Diabetes Obes Metab; 2011 Sep; 13(9):800-5. PubMed ID: 21477065
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.
    Rosenstock J; Vico M; Wei L; Salsali A; List JF
    Diabetes Care; 2012 Jul; 35(7):1473-8. PubMed ID: 22446170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pioglitazone is effective therapy for elderly patients with type 2 diabetes mellitus.
    Rajagopalan R; Perez A; Ye Z; Khan M; Murray FT
    Drugs Aging; 2004; 21(4):259-71. PubMed ID: 15012171
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative study of sitagliptin with pioglitazone in Japanese type 2 diabetic patients: the COMPASS randomized controlled trial.
    Takihata M; Nakamura A; Tajima K; Inazumi T; Komatsu Y; Tamura H; Yamazaki S; Kondo Y; Yamada M; Kimura M; Terauchi Y
    Diabetes Obes Metab; 2013 May; 15(5):455-62. PubMed ID: 23279373
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial.
    Stirban AO; Andjelkovic M; Heise T; Nosek L; Fischer A; Gastaldelli A; Herz M
    Diabetes Obes Metab; 2016 Jul; 18(7):711-5. PubMed ID: 26663152
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
    Pinget M; Goldenberg R; Niemoeller E; Muehlen-Bartmer I; Guo H; Aronson R
    Diabetes Obes Metab; 2013 Nov; 15(11):1000-7. PubMed ID: 23627775
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
    Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.
    Berhanu P; Perez A; Yu S
    Diabetes Obes Metab; 2007 Jul; 9(4):512-20. PubMed ID: 17587394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A multicenter, phase III evaluation of the efficacy and safety of a new fixed-dose pioglitazone/glimepiride combination tablet in Japanese patients with type 2 diabetes.
    Hiroi S; Sugiura K; Matsuno K; Hirayama M; Kuriyama K; Kaku K; Kawakami K
    Diabetes Technol Ther; 2013 Feb; 15(2):158-65. PubMed ID: 23289434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.
    Aronoff S; Rosenblatt S; Braithwaite S; Egan JW; Mathisen AL; Schneider RL
    Diabetes Care; 2000 Nov; 23(11):1605-11. PubMed ID: 11092281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and safety of colesevelam in combination with pioglitazone in patients with type 2 diabetes mellitus.
    Rosenstock J; Truitt KE; Baz-Hecht M; Ford DM; Tao B; Chou HS
    Horm Metab Res; 2014 Dec; 46(13):943-9. PubMed ID: 25054436
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Pareek A; Chandurkar N; Thomas N; Viswanathan V; Deshpande A; Gupta OP; Shah A; Kakrani A; Bhandari S; Thulasidharan NK; Saboo B; Devaramani S; Vijaykumar NB; Sharma S; Agrawal N; Mahesh M; Kothari K
    Curr Med Res Opin; 2014 Jul; 30(7):1257-66. PubMed ID: 24669876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.